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Target renal damage: the microvascular
associations of increased aortic stiffness in
patients with COPD
Michelle John1, Samia Hussain1, Andrew Prayle2, Rebecca Simms1, John R Cockcroft3 and Charlotte E Bolton1*
Abstract
Background: Although renal impairment has been described in COPD, there is opportunity to evaluate further to
determine nature and consider optimal management. Increased aortic stiffness, as seen in COPD, leads to reduced
buffering of pulsatile flow. We hypothesised that urinary albumin creatinine ratio (UACR) would reflect glomerular
damage related to aortic stiffness.
Methods: Patients with COPD and controls underwent spirometry, blood pressure, arterial stiffness - aortic pulse
wave velocity (PWV) and provided a spot urine sample for UACR, with other renal biomarkers measured.
Results: The UACR was increased in patients (n = 52): 0.80 mg/mmol compared to controls (n = 34): 0.46 mg/mmol,
p < 0.05. Aortic PWV was related to log10 UACR in all subjects (r = 0.426, p < 0.001) and COPD patients alone. Aortic
PWV was a significant variable for UACR with oxygen saturations, after accounting for potential confounders. Eight
subjects (7 patients) reached a defined clinical microalbuminuria threshold, with aortic PWV greater in these
patients compared to those patients without, although albuminuria is a continuum. Proximal tubular damage
biomarkers, unlike the glomerular marker, were not different between patients and controls.
Conclusions: There is glomerular damage in patients with COPD evidenced by increased UACR, related to
increased aortic stiffness. Besides the macrovascular prognostic implications of increased aortic stiffness, the
microvascular state in COPD management should be considered.
Keywords: Arterial stiffness, Biomarkers, Haemodynamics, Kidney, Renal, Microvascular
Background
Cardiovascular (CV) risk in chronic obstructive airways
disease (COPD) patients has been the interest of much
recent research, since CV disease contributes signifi-
cantly to the increased mortality associated with COPD
[1]. Often subclinical, increased aortic stiffness, [2,3]
altered haemostasis, [4] endothelial and ventricular dys-
function are likely contributing factors [3,5,6].
In addition to the macrovascular events associated with
increased aortic stiffness, there is also the microvascula-
ture association [7]. The renal and cerebral vascular beds
are particularly susceptible to the increased pulsatile flow
they are exposed to due to the reduced buffering capacity
of the large arteries, such as the aorta, associated with in-
creased arterial stiffness. Albuminuria reflects increased
permeability of the glomerulus, usually due to microvascu-
lar damage. Indeed, albuminuria has been related to all-
cause mortality as well as CV events [8,9], and suggested
as an early prognostic CV marker. It has been related to
arterial stiffness in subjects with diabetes and hypertension
[10-12], as well as in a non-diabetic, non-hypertensive
population [13], and the general population [14].
The proportion of patients with COPD having co-
existent renal impairment has been highlighted [15,16].
However, identification of renal disease on serum creatin-
ine or creatinine based estimated glomerular filtration rate
(eGFR) alone is likely to underestimate the prevalence;
further, the eGFR role in an older population has been
questioned. Casanova et al. [17] demonstrated increased
urinary albumin creatinine ratio (UACR) in patients with
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COPD and that microalbuminuria was frequent compared
to smokers; [17] being related to hypoxaemia and systolic
blood pressure. However, age was markedly different be-
tween the patients and controls – which can affect UACR.
Advances in specific renal biomarkers provide an oppor-
tunity to explore processes further. Neutrophil gelatinase-
associated lipocalin (NGAL) and kidney injury molecule −1
(KIM-1) are markers of proximal tubular damage; whilst
serum cystatin C is a measure of glomerular function, with
the advantage that unlike serum creatinine, cystatin is pro-
duced by every nucleated cell and is only eliminated by the
kidney.
We hypothesised that in addition to the prognostic in-
formation that increased aortic stiffness poses for future
cardiovascular events; the increased aortic stiffness in
patients with COPD relates to subclinical glomerular
injury.
Methods
Subjects
Subjects with a smoking history, with and without COPD,
over 40 years of age and of European ancestry were
recruited. All subjects gave written informed consent
and the study was performed in accordance with the
Declaration of Helsinki and approved by Leicester,
Nottingham and Rutlands Research Ethics Committee
(NRES ref 10/H0406/65). Subjects were excluded if known
alpha-1-antitrypsin deficiency, active or suspected malig-
nancy or terminal disease. We deliberately did not exclude
subjects with ischaemic heart disease (IHD) and diabetes
in order to represent clinical practice. However, we opted
a priori to compare controls and patients with COPD in
the subgroup without evidence of IHD or diabetes. All
subjects had smoked greater than 10 pack years. Controls
had no evidence of airways obstruction or history of re-
spiratory disease. COPD patients were studied at clinical
stability, defined as no change in regular therapy, no re-
quirement for antibiotics and/or oral corticosteroids in the
preceding 4 weeks and no change in symptoms beyond
day-day variation. Subjects were recruited from depart-
mental databases of volunteers and by poster and local
newspaper advert. Further, patients were also invited from
local out-patient COPD clinics.
Cardiovascular measurements
Patients were asked to refrain from short acting broncho-
dilators for four hours prior to the study. Tests were
performed after a period of resting supine for at least 10
minutes. Heart rate (HR) and peripheral blood pressure
(BP) were performed (Omron 705IT, UK). Pulse pressure
(PP) and mean arterial pressure (MAP) were calculated.
Aortic pulse wave velocity (PWV) was performed using
Vicorder (Skidmore Medical, UK). Sequentially recorded
ECG-gated carotid and femoral artery waveforms allowed
calculation of wave transit time by the system software,
using the R wave of a simultaneously recorded ECG as a
reference frame. Aortic PWV was determined by dividing
path length by wave transit time. Pulse wave analysis
(PWA) was used to generate a corresponding central wave-
form. With the integral software, augmentation index (AIx)
was calculated as the difference between the second and
first systolic peaks as a percentage of PP. Stroke Volume
was also calculated through integral software and corrected
for body surface area using the Mosteller calculation.
Anthropometry and lung function
Height and weight were measured and body mass index
(BMI) calculated. Fat free mass (FFM) was calculated
using bioelectrical impedance with the subject encour-
aged to void immediately prior to assessment (Tanita
418). A low BMI was defined as <20 kg/m2; a low FFMI
was defined as <15 kg/m2 in females and <16 kg/m2 in
males. Post-bronchodilator spirometry was performed
(Microlab MK6, Micromedical, UK) to determine forced
expiratory volume in one second (FEV1), forced vital
capacity (FVC) and the ratio FEV1/FVC. The Global ini-
tiative for chronic Obstructive Lung Disease (GOLD)
stage of airflow obstruction was used to classify patients
into GOLD stages I-IV. [18] Oxygen saturations after 10
minutes rest (Konica Minolta Pulsox-300) breathing air
and exhaled carbon monoxide levels were performed
(Clement Clarke).
Biochemistry
Venous blood was taken for urea, electrolytes, creatinine,
total cholesterol, HDL-cholesterol and triglycerides. Spot
morning urine sample was collected for urinary albumin
and creatinine to determine UACR. A clinical microalbu-
minuria threshold of 2.5 mg/mmol males and 3.5 mg/mmol
females was used; although there is growing awareness that
albuminuria is a continuum. All analytes were measured on
the Olympus AU2700 platform (Beckman Coulter, USA)
according to manufacturer’s settings. Creatinine was mea-
sured using the traditional O’Leary Beckman Coulter assay.
The eGFR was determined using Modification of Diet in
Renal Disease (MDRD) formula [19]. LDL-cholesterol levels
were estimated using the Friedewald equation [20]. All
methods had been fully quality controlled prior to analysis
in a CPA accredited laboratory.
Serum was centrifuged, aliquoted and stored at −80°C
for later determination of cystatin and C-reactive protein
(CRP) (R&D systems, UK). Urine aliquots were stored
at −80°C for later determination of NGAL and
KIM-1 (R&D systems, UK). All research ELISA’s were
performed in duplicate in batches. NGAL and KIM-1
were standardised for urine concentration according to
urinary creatinine.
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Other measurements
Detailed history including medication and smoking
were recorded. The COPD assessment tool (CAT) and
St George’s Respiratory Questionnaire (SGRQ) were
performed [21,22].
Statistics
Data was analysed using Statistical Package for the Social
Sciences (SPSS, Chicago, IL) version 19.0. Positively
skewed data was log10transformed in order to perform
parametric analysis where possible – UACR, CRP, NGAL
and KIM-1. Results for these variables are presented as
geometric mean and SD. Analyses included chi-squared
test for categorical data such as sex, independent t test
for comparisons between two groups of continuous data,
Pearson’s correlations to determine the nature of associ-
ations and stepwise multiple regression (see results sec-
tion for variables). A p < 0.05 was considered significant.
Results
The age, sex proportion and BMI were not different,
Table 1. Resting oxygen saturations of <92% on air were
present in 3 patients. There were 4 patients with a low BMI
but no controls, and 13 patients and 9 controls were
classed as obese (BMI >30 kg/m2). FFMI measurement was
not possible in every subject using BIA but 8/47 and 0/30
controls had a low FFMI. No subjects had a former diagno-
sis of renal disease and none had macroalbuminuria. There
were 5 patients and 1 control that were on ACE inhibitors;
2 patients and 0 controls on beta blockers. CRP was similar
between both groups, Table 2.
Subgroup analysis in subjects without diabetes or IHD
was performed: n = 40 patients and n = 29 controls. Again,
age, gender, BMI, MAP and smoking status were similar
between both groups.
Renal biomarkers
The mean eGFR was similar in patients and controls with
a similar proportion: 15/52 (29%) and 10/34 (29%) having
a low eGFR (<60 mls/min) based on serum creatinine.
The UACR was greater in patients than controls, p < 0.05,
Table 3 and Figure 1. In the subgroup without diabetes or
IHD, again UACR was greater in the patients than
controls: geometric mean (SD) 0.82 (3.76) and 0.45 (3.55)
mg/mmol respectively, p = 0.06. Age was related to
log10UACR, r = 0.321, p = 0.003 in the whole group and
subgroup without diabetes or IHD, r = 0.357, p = 0.003.
Further, in the whole population, log10UACR was inversely
related to FEV1% predicted in all subjects (r = −0.231, p =
0.033) but not in COPD alone and to oxygen saturations
in all subjects (r = −0.284, p = 0.008) and patients with
COPD alone (r = −0.294, p = 0.03). It was not related to
smoking pack years, BMI or FFMI.
There were 7 (13%) patients with COPD and 1 (3%)
smoker control who had a UACR consistent with a clin-
ical threshold for microalbuminuria. Of these 8, 1 was a
patient with COPD who had co-existent diabetes. The
other 7 had no history of diabetes or IHD.
The proximal tubule urinary markers of KIM-1/Cr and
NGAL/Cr were not different between all controls and pa-
tients with COPD, Table 2. Cystatin C was not different
between all patients with COPD and controls. Log10
cystatin C was related to eGFR (r = −0.476, p < 0.001);
a greater cystatin C suggesting functional impairment.
Haemodynamics
Aortic PWV was greater in patients than controls despite
similar MAP, Table 3. In the subgroup without a past
Table 1 Subject demographics
Control smoker COPD P value
n 34 52
Age (years) 66(11) 68 (8) 0.3
Gender male:female 17:17 31:21 0.38
Smoking status current:ex 9:25 13:39 0.88
Smoking pack years 29(18) 39 (21) 0.017
FEV1 (L) 2.6(0.7) 1.5 (0.6) <0.001
FEV1 % predicted (%) 99 (13) 59(20) <0.001
FVC (L) 3.6(1.1) 3.1(1.0) 0.05
FVC % predicted (%) 109(16) 95 (20) 0.001
Oxygen saturations (%) 96(1) 95 (2) 0.001
Carbon monoxide (ppm) 9(10) 7(8) 0.47
CAT score 5(5) 17(10) <0.001
SGRQ 7(7) 37(21) <0.001
GOLD stage of airflow
obstruction 1/2/3/4 (n)
0/0/0/0 5/33/10/4
BMI (kg/m2) 27.0 (3.4) 26.3(4.8) 0.44
FFMI (kg/m2) n = 77 18.8 (2.3) 18.2 (2.5) 0.31
IHD (n) 2 9 0.12
Diabetes (n) 4 5 0.75
All results are presented as mean (SD) unless otherwise stated.
Abbreviations: FEV1 forced expiration in 1 second; FVC forced vital capacity;
CAT COPD assessment Test; SGRQ St George’s respiratory questionnaire;
GOLD Global initiative for chronic Obstructive Lung Disease; BMI body mass
index; FFMI fat free mass index; IHD ischaemic heart disease.
Table 2 Renal and inflammatory biomarkers
Control smoker COPD P value
Urinary KIM-1 / Cr † ng/g 513 (2) 575 (2) 0.423
Urinary NGAL / Cr † ng/g 16982 (2) 16218 (2) 0.804
Serum Cystatin C ng/ml 818 (295) 874 (258) 0.358
CRP † mg/ ml 1.1 (2.3) n = 34 1.4 (2.3) n = 49 0.110
All results are presented as mean (SD) unless otherwise stated.
† Geometric Mean.
Abbreviations: KIM-1 Kidney injury molecule 1; NGAL Neutrophil gelatinase-
associated lipocalin; Cr Creatinine; CRP C reactive protein.
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history of diabetes or IHD, the mean (SD) aortic PWV
was greater in patients, 10.9 (1.7) m/s compared to con-
trols, 9.6 (2.2) m/s, p = 0.011. In the whole population, de-
rived stroke volume index was similar between groups.
Log10 UACR was related to aortic PWV in all subjects
(r = 0.426, p < 0.001) and in COPD patients alone (r =
0.316, p = 0.022), Figure 2. The association of log10UACR
with aortic PWV, FEV1% predicted and oxygen saturations
were also present in the subgroup without IHD or
diabetes: aortic PWV r = 0.494, p < 0.001; FEV1% predicted
r = −0.285, p = 0.018; oxygen saturations r = −0.326, p =
0.007.
Multiple stepwise regressions were performed with
log10UACR as the dependent and age, gender, FEV%,
peripheral MAP, BMI, smoke pack years, aortic PWV,
oxygen saturations, IHD and diabetes as the independ-
ent variables, Table 4. In all subjects and in patients with
COPD alone both aortic PWV and oxygen saturations
were significant variables. The same held when periph-
eral MAP was substituted for peripheral PP or central
MAP or central PP.
Aortic PWV was greater in the 7 patients with
microalbuminuria: 12.3 (2.4) m/s compared to the patients
without: 10.6 (1.7) m/s, p = 0.023; and remained after ad-
justment for age and gender.
There was no relationship between log10CRP and aortic
PWV. As expected, there was no relationship of either
KIM-1 or NGAL with aortic PWV, or in deed with any of
the other variables: FEV1% predicted or oxygen saturation
in either all subjects or COPD alone.
Discussion
COPD patients have increased UACR compared to con-
trols which was related to the increased aortic stiffness.
The UACR increase in the presence of similar biomarkers
of proximal tubular damage would reinforce the glomeru-
lar damage leading to increased permeability in patients.
Aortic stiffness was an independent variable of UACR in
the setting of similar peripheral BP measures, with BP if
anything marginally lower in patients with COPD.
The recent GOLD document has embedded that
comorbidities are important to detect and manage in pa-
tients with COPD [18]. One of the co-morbidities
highlighted as frequent and important was cardiovascular
Table 3 Haemodynamic status and biochemistry
Control smoker COPD P value
eGFR (ml/min) 67 (12) 67 (14) 0.91
UACR † (mg/mmol) 0.46 (3.24) 0.80 (3.66) 0.046
Aortic PWV (m/s) 9.9 (2.3) 10.8 (1.9) 0.051
Peripheral Systolic BP (mmHg) 150 (22) 144 (20) 0.147
Peripheral Diastolic BP (mmHg) 87 (11) 83 (11) 0.102
Peripheral Pulse pressure (mmHg) 63 (17) 60 (17) 0.497
Peripheral MAP (mmHg) 108 (13) 104 ( 12) 0.078
Heart rate (bpm) 69 (11) 77 (17) 0.014
AIx (%) 21 (6) 21 (15) 0.957
Central Pulse Pressure (mmHg) 56 (15) 54 (14) 0.65
Central MAP (mmHg) 106 (14) 104 (12) 0.67
Stroke Volume Index (ml/m2) 44.9 (13.9) 44.9 (10.7) 0.99
Total Cholesterol (mmol/L) 5.0 (1.2) 5.1 (1.1) 0.613
LDL-Cholesterol (mmol/L) 2.5 (1.0) 2.7 (1.0) 0.618
HDL-Cholesterol (mmol/L) 1.6 (0.4) 1.8 (0.5) 0.058
All results are presented as mean (SD) unless otherwise stated.
† geometric mean.
Abbreviations: eGFR estimated glomerular filtration rate; UACR urinary albumin creatinine ratio; IHD ischaemic heart disease; PWV pulse wave velocity; BP blood
pressure; MAP mean arterial pressure; AIx augmentation index.
Figure 1 Urinary albumin creatinine ratio in all patients with
COPD and controls. Median and IQR.
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disease. Recommendations encourage healthcare profes-
sionals to manage the co-morbidity in general, as if the pa-
tient does not have COPD. However, this fundamentally
relies on diagnosing the co-morbidity in the first instance
and a robust platform of assessment to monitor response
and progression. If renal changes are related to the altered
haemodynamics, it is imperative that we fully evaluate
the interplay of microvasculature to the macrovascular
state in COPD. In COPD patients, associations of aortic
stiffness with UACR were demonstrated despite only a
small proportion above the threshold defining clinical
microalbuminuria. The striking increased aortic PWV in
those patients with newly identified microalbuminuria rein-
forces the clinical context. Albuminuria, though, is a
continuum and measureable renal injury occurs below the
arbitrary threshold for microalbuminuria [23,24].
A decision was made to include all patients with con-
firmed COPD, irrespective of co-existent comorbidities
such as IHD and diabetes. This is a different approach
to previous studies we have conducted but has been
widely adopted by others. We opted a priori that this
would a) represent a more typical COPD population
seen in clinic and b) if there are subclinical changes in
patients, then exclusion of a subset with prior diagnosed
disease seemed arbitrary and may relate to diagnosis as
opposed to presence.
Although a greater proportion of COPD patients who
have a low eGFR compared to controls has been reported,
the utility of a creatine-based eGFR as a measure of renal
impairment in older populations is debateable, particularly
in conditions associated with altered body composition
[25]. The large proportion of subjects in both groups with
impaired eGFR in this study is striking but likely due to
the older nature of subjects. The advent of the biomarker
era permits the ability to untangle potential anatomical
sites for nephropathy. The similar concentration-corrected
NGAL and KIM-1 proximal tubular biomarkers lend sup-
port to the increased urinary albumin being a primary
glomerular injury. We understand this is the first to study
these in COPD patients in such a comprehensive manner.
A number of studies have explored different formulae
for cystatin C derived eGFR in a variety of populations.
The most widely used in an unselected population is the
Grubb equation which has been validated against the gold
standard (invasive) method of plasma iohexol clearance
[26]. Given none of the various equations have compared
cystatin C to a gold standard in COPD we opted to
present the cystatin C alone [27]. Cystatin C measures
glomerular function and it is therefore not all-together un-
expected that a marked difference in glomerular damage
markers was seen despite similar cystatin C.
The association of glomerular damage to microvas-
culopathy has been demonstrated in subjects with other
conditions such as hypertension and diabetes, both condi-
tions associated with increased aortic stiffness [28,29]. In
order to interrogate whether aortic stiffness leads to micro-
vascular damage via altered renal haemodynamics, renal
doppler sonography permits calculation of the renal artery
vascular resistance. Such studies have demonstrated associ-
ations of a resistive index to proteinuria in patients with
chronic kidney disease with and without diabetes mellitus;
[30] to albuminuria and also a measure of aortic stiffness
(brachial-ankle) in 150 patients with type 2 diabetes
mellitus; [31] and in patients with hypertension, a modest
increase in renal resistive index was associated with a
greater adjusted relative risk of albuminuria [32]. Fesler and
colleagues highlighted the importance of PP (as a marker of
arterial stiffness) in longitudinal change in renal decline
Figure 2 Association of urinary albumin creatinine ratio to
aortic stiffness in patients with COPD and controls. Solid
Circle – COPD, Open Circle – Control smokers, Dotted line – All
subjects (r = 0.426, p < 0.001), Black line – COPD (r = 0.316, p = 0.022),
Dashed line - Control smokers (r = 0.524, p = 0.001).
Table 4 Results of stepwise multiple regression analysis,
with Log10UACR as dependent variable and age, gender,
FEV1%, MAP, BMI, smoke pack years, aortic PWV, oxygen
saturations, IHD and diabetes as the independent
variables
A) In all subjects B (95% CI) Overall adjusted r2
Constant 5.57 (0.16, 11.0)
Aortic PWV 0.11 (0.06, 0.16)
Oxygen saturations −0.07 (−0.13, -0.02) 22.5%
B) In COPD patients B (95% CI) Overall adjusted r2
Constant 6.39 (−0.16, 12.95)
Aortic PWV 0.10 (0.02, 0.18)
Oxygen Saturation −0.08 (−0.15, -0.01) 15.9%
The significant independent variables are shown in the Table.
Abbreviations: PWV pulse wave velocity; MAP mean arterial pressure; BMI
body mass index; FEV1%, forced expiratory volume in one second %
predicted; UACR urinary albumin creatinine ratio.
Performed in A) all subjects (COPD and controls), B) patients with COPD alone.
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whilst treating hypertension [33]. Conversely, there is the
opposing argument in a biological system - Wang reported
the utility of low grade albuminuria to determine progres-
sion to hypertension in a non-hypertensive and non-
diabetic population over nearly 3 years [34]. This study
confirms and highlights the issue in COPD which has not
been previously demonstrated.
Increased permeability due to impaired filtration of the
barrier may be due to direct podocyte injury but other po-
tential reasons for the association may be mediated via
systemic inflammation, hypoxaemia, endothelial dysfunc-
tion or increased sympathetic activation, all known to be
affected in COPD [35-37]. Resting oxygen saturations
were a significant variable of albuminuria in our study.
This has been reported previously in patients with COPD
and in other conditions and states such as with altitude in
healthy volunteers [17,38]. Sympathetic activation is
known to increase arterial stiffness and raises an interest-
ing consideration that therapeutic modulation, such as
with ACE inhibitors, that are CV protective, decrease sym-
pathetic nervous system (SNS) activation and confer renal
benefit might have a role in COPD. In a parallel manner,
beta blockers inhibit SNS activity and have been shown to
improve mortality in COPD although their effect on renal
function is as yet unknown [39]. Although there was no
association with circulating CRP in this study, systemic
inflammation cannot be excluded as a mediator. Similarly,
endothelial dysfunction and albuminuria remains a strong
contender [40]. The most likely cause is the inter-play of a
combination of several factors above or even foetal
programming but beyond the scope of this study [41].
The relationship between arterial stiffness and atheroma
is still not well understood and at present conventional risk
factors, except BP and age do not account for much of the
increased arterial stiffness. However, increased stiffness has
many non atherosclerotic deleterious associations including
increased pulsatility [42]. Identification of microvascular ab-
normalities such as increased UACR is important and pro-
vides an opportune and influential period to intervene prior
to development of macrovascular disease [43].
Points for consideration
When considering UACR, it is important to reflect on
the spot test which is now accepted over twenty-four
hour urine collection and has been validated [25]. UACR
was measured contemporaneously from fresh urine [44].
The timing of urinary spot samples is often debated des-
pite low diurnal variation–here morning samples where
possible, avoiding first void were collected.
Pack years were not matched however all had a pack year
history of greater than 10. All were of European ancestry as
this could have affected haemodynamic and glomerular re-
sults. Unlike previous studies in patients with and without
COPD, we did not demonstrate a difference in AIx as a
secondary variable. The Stroke Volume index is derived
and the method requires further evaluation.
Conclusion
In conclusion, there is evidence of increased urinary albu-
min in patients with COPD which is independently related
to aortic stiffness. As in other conditions with altered
haemodynamics, identification of glomerular damage is
important. The study highlights consideration regarding
intervention to optimise the CV state in COPD manage-
ment and the potential role of measurement of urinary
albumin in routine assessment of COPD.
Abbreviation
AIx: Augmentation index; BMI: Body mass index; BP: Blood pressure;
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